



Company Overview

Fortress Biotech, Inc. ("Fortress") is an innovative biopharmaceutical company that was recently ranked number 10 in Deloitte's 2019 Technology Fast 500™, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentage of fiscal year revenue growth over a three-year period. Fortress is focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical product candidates. The company has five marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company's portfolio of product opportunities. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals Inc. (a subsidiary of Cipla Limited), St. Jude Children's Research Hospital and Nationwide Children's Hospital.

Mustang Bio Announces Orphan Drug Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency ("XSCID") in Previously Transplanted Patients

Sep 22 2020, 8:00 AM EDT

Checkpoint Therapeutics Announces \$20.0 Million Bought Deal Offering

Sep 17 2020, 5:27 PM EDT

Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Sep 17 2020, 6:30 AM EDT

Management Team

Lindsay A. Rosenwald, M.D.

Chairman, President and Chief Executive Officer

Michael S. Weiss

Executive Vice Chairman, Strategic Development

Robyn Hunter

Chief Financial Officer

George Avgerinos, Ph.D.

Senior Vice President, Biologics Operations

Fortress Biotech, Inc.

2 Gansevoort Street
9th Floor
New York, NY 10014

Stock Overview

Symbol	F BIO
Exchange	Nasdaq
Market Cap	346.75m
Last Price	\$3.94
52-Week Range	\$1.04 - \$4.78

Investor Relations

Jaclyn Jaffe
T: 781-652-4500
ir@fortressbiotech.com

09/28/2020 04:00 PM EDT

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.